Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Bristol-Myers Squibb Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
An examination of the investment activity ratios reveals distinct trends over the observed period. Generally, the ratios demonstrate fluctuations, with a notable shift in performance beginning in the first quarter of 2024. The analysis focuses on net fixed asset turnover, total asset turnover, and equity turnover to assess the efficiency with which assets are utilized to generate revenue.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio exhibited a gradual decline from 7.77 in March 2022 to 6.39 in December 2025. This indicates a decreasing efficiency in generating revenue from fixed assets. The decline was relatively consistent throughout 2022 and 2023, accelerating slightly in 2024 and 2025. This suggests potential underutilization of fixed assets or a shift in the company’s revenue generation strategy away from fixed asset-intensive processes.
- Total Asset Turnover
- The total asset turnover ratio showed a more stable pattern initially, fluctuating between 0.46 and 0.49 from March 2022 through December 2023. A clear upward trend emerged starting in March 2024, increasing from 0.46 to 0.54 by December 2025. This suggests improved efficiency in utilizing all assets to generate revenue. The increase is particularly noticeable in the latter half of the observed period, indicating a positive shift in asset management practices.
- Equity Turnover
- The equity turnover ratio remained relatively stable between 1.41 and 1.55 from March 2022 to September 2023. A significant increase is observed beginning in March 2024, rising from 2.76 to 2.61 in December 2025, with a peak of 2.96 in December 2024. This substantial rise indicates a considerably improved ability to generate revenue from shareholders’ equity. The increase suggests a more effective utilization of equity financing or a change in capital structure.
In summary, while the efficiency of generating revenue from fixed assets has decreased, the company demonstrates improving efficiency in utilizing total assets and equity. The contrasting trends suggest a strategic shift in asset allocation and revenue generation methods, with a growing reliance on assets other than fixed assets and a more effective use of equity. The increases in total asset and equity turnover, particularly from 2024 onwards, are positive indicators of improved financial performance.
Net Fixed Asset Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Property, plant and equipment | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Net fixed asset turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Property, plant and equipment
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The net fixed asset turnover ratio experienced a general declining trend over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrated relative stability, followed by a more pronounced decrease in later periods. This indicates a shifting relationship between revenue generation and the investment in fixed assets.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The ratio began at 7.77 and fluctuated around the 7.7 to 7.9 range for the first three quarters. A slight decrease to 7.38 was observed by the end of 2022, suggesting a modest reduction in the efficiency of fixed asset utilization.
- Continued Decline (Mar 31, 2023 – Dec 31, 2024)
- The downward trend accelerated in 2023, with the ratio declining from 7.30 in March to 6.77 by December. This decline continued into 2024, reaching a low of 6.75 in March. While some fluctuation occurred throughout 2024, the ratio remained consistently below the levels observed in 2022.
- Recent Period (Mar 31, 2025 – Dec 31, 2025)
- The ratio exhibited further decline in 2025, starting at 6.60 in March and ending at 6.39 in December. This represents the lowest point within the analyzed timeframe, indicating a continued decrease in revenue generated per dollar of fixed assets.
- Revenue and Fixed Asset Trends
- Revenues generally increased over the period, from US$11,648 million to US$12,502 million. However, property, plant, and equipment also increased, from US$6,047 million to US$7,543 million. The increase in fixed assets outpaced the increase in revenue, contributing to the observed decline in the net fixed asset turnover ratio.
The consistent decrease in the net fixed asset turnover ratio suggests that the company is becoming less efficient in utilizing its fixed assets to generate revenue. This could be due to several factors, including increased investment in fixed assets without a corresponding increase in revenue, or a decrease in the productivity of existing fixed assets. Further investigation would be required to determine the underlying causes of this trend.
Total Asset Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Total assets | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Total asset turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The total asset turnover ratio exhibits a generally increasing trend over the observed period, with some quarterly fluctuations. Initially, the ratio ranged between 0.46 and 0.49 from March 2022 to December 2022. A subsequent increase is noted, peaking at 0.54 in December 2025, indicating improved efficiency in asset utilization. The ratio demonstrates a degree of volatility, but the overall direction suggests a strengthening relationship between revenue generated and assets employed.
- Initial Phase (Mar 31, 2022 – Dec 31, 2022)
- The ratio began at 0.46 and fluctuated between 0.46 and 0.48 over this period. This suggests a relatively stable, but modest, level of asset utilization. There is no clear directional trend within this initial timeframe.
- Growth Phase (Mar 31, 2023 – Dec 31, 2024)
- From March 2023, the ratio experienced a gradual increase, reaching 0.52 by December 2024. This indicates a growing efficiency in generating revenue from the company’s asset base. The increase from 0.49 to 0.52 represents a notable improvement in asset utilization.
- Peak and Recent Performance (Mar 31, 2025 – Dec 31, 2025)
- The ratio reached its highest point of 0.54 in December 2025. This suggests that the company is becoming increasingly effective at converting its investments in assets into sales. The most recent quarterly value indicates a sustained level of efficient asset management.
The observed increase in the total asset turnover ratio is a positive indicator. It suggests that the company is either increasing sales volume with the same level of assets, or reducing its asset base while maintaining sales levels, or a combination of both. Further investigation into the underlying drivers of revenue and asset changes would be necessary to determine the specific factors contributing to this trend.
Equity Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Total BMS shareholders’ equity | |||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Equity turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Total BMS shareholders’ equity
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The equity turnover ratio for the analyzed period demonstrates a notable shift in trend. Initially, the ratio exhibited relative stability, followed by a significant increase in later periods.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- From March 31, 2022, through December 31, 2022, the equity turnover ratio fluctuated within a narrow range, between 1.41 and 1.49. This suggests a consistent relationship between revenues generated and the level of shareholders’ equity employed during this timeframe. A slight decrease is observed from 1.49 to 1.41, then a recovery to 1.49, indicating minor variations in operational efficiency regarding equity utilization.
- Transitional Phase (Mar 31, 2023 – Dec 31, 2023)
- The first three quarters of 2023 show a continuation of the relatively stable pattern, with the ratio ranging from 1.41 to 1.55. However, the final quarter of 2023 shows a slight increase to 1.53, hinting at a potential shift in the relationship between revenues and equity.
- Significant Increase (Mar 31, 2024 – Dec 31, 2025)
- A substantial increase in the equity turnover ratio is evident beginning in March 2024. The ratio jumps to 2.76 and remains elevated, fluctuating between 2.59 and 2.96 over the subsequent quarters. This indicates a significantly improved efficiency in generating revenue from the company’s equity base. The ratio remains above 2.60 through the end of the analyzed period, suggesting this is not a temporary fluctuation but a sustained change. This increase coincides with a substantial decrease in total shareholders’ equity, while revenues remained relatively stable or increased.
Overall, the trend suggests a considerable improvement in the efficiency with which the company utilizes shareholders’ equity to generate revenue, particularly from March 2024 onwards. The substantial increase in the equity turnover ratio warrants further investigation to understand the underlying drivers, such as changes in asset utilization, financial leverage, or equity structure.